Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States
Muscle & Nerve · 2024-02 · 69 (2) · 157-165
DOI: 10.1002/mus.27992 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Muscle & Nerve, online erschienen am 29.11.2023. Verfasst von A Parthan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Myasthenia Gravis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.
Abstract (Originalsprache)
Introduction/Aims If myasthenia gravis (MG) symptoms are inadequately controlled, patients may experience exacerbations or life‐threatening myasthenic crises. Patients with inadequately controlled MG symptoms tend to be treated with chronic intravenous immunoglobulin (IVIg) therapy and/or multiple immunosuppressant therapies (ISTs). This study aimed to examine disease burden, healthcare resource utilization, and associated costs in these patients.
Methods
This was a retrospective observational study using a claims database. Patients with MG were classified into three cohorts based on treatment over a 1‐y follow‐up period: (a) treated with four or more IVIg episodes (chronic IVIg cohort); (b) received two or more non‐steroidal ISTs (NSISTs) sequentially (multiple NSIST cohort); (c) received neither chronic IVIg nor multiple NSISTs (reference cohort). Incidences of crises and exacerbations and annual healthcare costs in each cohort were estimated.
Results
In total, 3516 patients with MG were included in the analysis. Compared with the reference cohort ( n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg ( n = 324) and multiple NSIST ( n = 291) cohorts ( p < 0.001); and the MG exacerbation rate was approximately four‐fold higher in the chronic IVIg cohort ( p < 0.001) and three‐fold higher in the multiple NSIST cohort ( p < 0.001). Median annual MG‐related inflation‐adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).
Discussion
The burden of crises/exacerbations was substantially higher and healthcare costs were considerably greater in patients with MG treated with chronic IVIg or multiple NSISTs than in patients not receiving these treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
- Genesis Research Group, Hoboken, New Jersey, USA.
- University of California, Irvine, California, USA.
ORCID-Profile: A Parthan, M Royston, A Thanataveerat, E L East, C S Parzynski, A A Habib
Förderung
- Alexion, AstraZeneca Rare Disease
- Alexion Pharmaceuticals
Zitieren
APA
Parthan, A., Royston, M., Thanataveerat, A., East, E. L., Parzynski, C. S., & Habib, A. A. (2024). Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. Muscle & Nerve, 69(2), 157-165. https://doi.org/10.1002/mus.27992
Vancouver
Parthan A, Royston M, Thanataveerat A, East EL, Parzynski CS, Habib AA. Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. Muscle & Nerve. 2024;69(2):157-165. doi:10.1002/mus.27992
BibTeX
@article{Parthan2024,
author = {Parthan, A and Royston, M and Thanataveerat, A and East, E L and Parzynski, C S and Habib, A A},
title = {Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States},
journal = {Muscle & Nerve},
year = {2024},
volume = {69},
number = {2},
pages = {157--165},
doi = {10.1002/mus.27992}
}
EUVIMED